D-3263

Investigational

Details

Stereochemistry	ACHIRAL
Molecular Formula	C21H31N3O3
Molecular Weight	373.4891
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

SMILES

COC1=CC=C2N(C(=O)[C@@H]3C[C@H](C)CC[C@H]3C(C)C)C(=O)N(CCN)C2=C1

InChI

InChIKey=ZGTYTFYRCIRWBL-HYVNUMGLSA-N

InChI=1S/C21H31N3O3/c1-13(2)16-7-5-14(3)11-17(16)20(25)24-18-8-6-15(27-4)12-19(18)23(10-9-22)21(24)26/h6,8,12-14,16-17H,5,7,9-11,22H2,1-4H3/t14-,16+,17-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C21H31N3O3
Molecular Weight	373.4891
Charge	0
Count	MOL RATIO 1 MOL RATIO (average)

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Targets

Targets

Primary Target	Pharmacology	Condition	Potency
Transient receptor potential cation channel subfamily M member 8 18	Agonist 2,678

Substance Class	Chemical
Record UNII	70FBL3TX3E
Record Status	`Validated (UNII)`
Record Version

Show entries

Name

Type

Language

D-3263

Code

English

D 3263 [WHO-DD]

Common Name

English

3-(2-AMINOETHYL)-1-((1R,2S,5R)-2-ISOPROPYL-5-METHYL-CYCLOHEXANECARBONYL)-5-METHOXY-BENZIMIDAZOL-2-ONE

Systematic Name

English

2H-BENZIMIDAZOL-2-ONE, 3-(2-AMINOETHYL)-1,3-DIHYDRO-5-METHOXY-1-(((1R,2S,5R)-5-METHYL-2-(1-METHYLETHYL)CYCLOHEXYL)CARBONYL)-

Systematic Name

English

D-3263 (FREE BASE)

Code

English

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Code System

Code

Type

Description

PUBCHEM

44137358

PRIMARY

CLINICAL_TRIALS.GOV

D-3263 (FREE BASE)

PRIMARY

Official Title: A Phase 1, Open Label, Dose Escalation Study Evaluating the Safety and Pharmacokinetics of Enteric Coated D-3263 Hydrochloride in Subjects With Advanced Solid TumorsPurpose: This is a Phase 1, dose escalation study evaluating safety and pharmacokinetics of enteric coated D-3263 HCl in subjects with advanced solid tumors.

CAS

947257-66-1

PRIMARY

FDA UNII

70FBL3TX3E

PRIMARY

NCI_THESAURUS

C162345

PRIMARY

Showing 1 to 5 of 5 entries

Previous1Next

Show entries

Related Record

Type

Details


					R82GTC01OB

D-3263 HYDROCHLORIDE

SALT/SOLVATE -> PARENT


					UFM9CFV381

TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL SUBFAMILY M MEMBER 8

TARGET -> AGONIST

Showing 1 to 2 of 2 entries

Previous1Next

Show entries

Related Record

Type

Details


					70FBL3TX3E

D-3263

ACTIVE MOIETY

Comments:

Originator: Dendreon Corporation; Class: Antineoplastic, Small molecule; Mechanism of Action: Apoptosis stimulant, TRPM8 protein stimulant; Highest Development Phases: Suspended for Benign prostatic hyperplasia, Solid tumours; Most Recent Events: 31 Dec 2013 Suspended - Phase-I for Solid tumours in USA (PO), 31 Dec 2013 Suspended - Preclinical for Benign prostatic hyperplasia in USA (PO), 01 Dec 2011 Dendreon completes its phase I trial for Solid tumours in USA (NCT00839631)

Showing 1 to 1 of 1 entries

Previous1Next